Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter sold 5,903 shares of Common Stock in an open-market transaction at a price of $254.50 per share on May 11, 2026. The sale was made pursuant to a pre-established Rule 10b5-1 trading plan.
Following this transaction, Schechter directly holds 107,234 shares of Labcorp Common Stock, indicating he retains a substantial equity position in the company while executing a planned share sale.
Adam H. Schechter filed a Form 144 notifying an intended sale of common stock.
The notice lists 5,903 shares related to restricted stock vesting reported with Fidelity Brokerage Services LLC and records two recent dispositions in the prior three months: 5,273 shares on 02/11/2026 and 8,705 shares on 03/03/2026.
LH submitted a Form 144 notice reporting an insider sale and recent vested issuances. The filing shows 548 shares sold on 02/27/2026 for $155,999.54. The report lists multiple restricted stock vesting events (examples: 03/26/2026 3,659 shares; 03/27/2025 1,973 shares) and an ESPP purchase on 06/30/2025.
Labcorp Holdings Inc. reported first-quarter 2026 revenues of $3,537.6 million, up 5.8% from 2025, driven by 3.1% organic growth, acquisitions, and favorable currency. Diagnostics Laboratories contributed $2,762.1 million (5.0% growth) and Biopharma Laboratory Services $780.6 million (8.2% growth).
Net earnings attributable to Labcorp rose to $277.8 million from $212.8 million, with diluted EPS increasing to $3.35 from $2.52. Cost of revenues fell slightly as a percentage of sales and SG&A leveraged on higher revenue, supporting operating income of $380.8 million.
Operating cash flow improved sharply to $191.5 million. The company spent $202.2 million on acquisitions, including Empire City Laboratories, and repurchased 0.4 million shares for $98.0 million. It ended the quarter with $981.1 million in cash, a new $750.0 million term loan, ongoing share repurchase authorization, and a quarterly dividend of $0.72 per share.
Labcorp Holdings reported solid growth for the first quarter ended March 31, 2026 and raised its full‑year 2026 outlook. Revenue reached $3.54 billion, up 5.8% from $3.35 billion a year ago, driven by both Diagnostics Laboratories and Biopharma Laboratory Services.
Diluted EPS rose to $3.35 from $2.52, while Adjusted EPS increased 10.6% to $4.25. Operating income improved to $380.8 million and adjusted operating margin expanded to 14.4% from 14.0%. Free cash flow swung to $70.5 million from negative $107.5 million, helped by higher cash earnings.
Diagnostics revenue grew 5.0% to $2.76 billion with adjusted margin of 16.6%, and Biopharma revenue grew 8.2% to $780.6 million with a 15.5% adjusted margin. Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid $61.2 million in dividends.
For 2026, the company now targets enterprise revenue of $14.65–$14.80 billion (5.0–6.1% growth) and Adjusted EPS of $17.70–$18.35, modestly above its prior ranges.
Vanguard Capital Management reports beneficial ownership of 6,201,512 shares of Labcorp Holdings Inc common stock, representing 7.52% of the class as of 03/31/2026. The filing shows sole voting power of 825,392 shares and sole dispositive power over 6,201,512 shares. The Schedule 13G is signed on 04/28/2026 by Ashley Grim.
Labcorp Holdings Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on May 21, 2026 to elect eleven directors, approve executive pay on an advisory basis, and ratify Deloitte & Touche LLP as auditor for 2026.
For 2025, Labcorp reports revenues of $14.0 billion versus $13.0 billion last year, diluted EPS of $10.46 versus $8.84, adjusted EPS of $16.44 versus $14.57, and free cash flow of $1.2 billion versus $1.1 billion. Management highlights 13 transactions with health systems and labs, more than 130 new tests launched in high‑growth areas, and technology and AI tools to support diagnostics and clinical trials.
The proxy emphasizes board refreshment, with ten of eleven nominees independent and 64% overall diversity, strong shareholder engagement with meetings representing over 80% of shares, and a pay‑for‑performance philosophy where about 76% of the CEO’s 2025 target compensation and 69% for other named executives are performance‑based and at risk.
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on June 11, 2026 to stockholders who are on record at the close of business on May 29, 2026.
The company highlights its global scale, noting nearly 71,000 employees serving clients in about 100 countries and performing more than 750 million tests annually, as well as providing support for 85% of new drugs and therapeutic products approved by the FDA in 2025.
Labcorp Holdings Inc. will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026, and will host a conference call and webcast at 9:00 a.m. ET to discuss the results.
The earnings press release and financial information will be posted on the Labcorp Investor Relations website, where a link to the webcast and a replay available for one year will also be provided. Labcorp is described as a global leader in laboratory services, with nearly 71,000 employees serving clients in about 100 countries.